en · de · es · pt
assay-notes.peptides4800.com › Info › Administration, Testing And Availability — Research Overview

Administration, Testing And Availability — Research Overview

By Editorial Desk · published 2025-12-19 · last reviewed 2026-01-31 · Info

This is a working overview of Tuftsin, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2026-01-31. Anything still debated is marked as such rather than presented as settled.

Administration, Testing and Availability

Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.

Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.

Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.

Analytical Methods and Material Handling

Purity assessment relies mainly on reverse-phase high-performance liquid chromatography with ultraviolet detection. Because the peptide lacks a strong chromophore, detection often uses backbone absorbance near 214 nm. Identity is confirmed by mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, comparing the measured mass against the expected value. Amino acid analysis can verify composition after acid hydrolysis. Diastereomer content and residual counterions are reported less often, although both can influence biological assays.

Lyophilized material is generally stable for extended periods when kept dry at or below minus twenty degrees Celsius. Working solutions are less stable, and common practice is to aliquot and freeze them so that repeated freeze-thaw cycles are avoided. Aqueous solutions are sensitive to pH extremes and to microbial growth, so short-term storage at refrigerator temperature is typical. Oxidation and hydrolysis are the principal degradation routes. Reconstitution with sterile water or a mild buffer is standard, and solutions should be protected from light.

Selank at a glance

PropertyValueNotes
Common routeIntranasalAlso injected in some animal work
Solubility classFreely soluble in waterSolid form is hygroscopic
Typical storageAbout -20 degrees CelsiusKeep desiccated and dark
Purity methodReverse-phase HPLCReported as area percent
Confirmatory methodMass spectrometryVerifies expected molecular mass

Selank Handling, Stability, and Analysis

Once dissolved, the peptide is markedly less stable than the dry powder. Aqueous solutions are subject to backbone hydrolysis and to microbial growth when they are handled without sterile technique. Buffered solutions near neutral pH are common for short-term laboratory work, while acidic conditions are sometimes used to improve solubility. Analytical laboratories generally prepare working solutions fresh rather than storing them, and a residual water film left in a reopened vial can seed degradation even when the container appears dry.

Reversed-phase high-performance liquid chromatography is the standard technique for estimating peptide purity. The result is a peak-area percentage, which describes how much of the detected material elutes as the main peak in one run. Mass spectrometry confirms the molecular mass and can reveal truncated, adducted, or otherwise modified species. Amino acid analysis or tandem mass spectrometry can address sequence fidelity when identity is in doubt. None of these measurements, taken alone, establishes that a sample is fit for any specific purpose.

Lyophilized selank is normally supplied as a dry powder and is considered stable for extended periods when kept cold and dry. Moisture uptake is the main practical threat, because absorbed water promotes both hydrolysis and aggregation in the solid state. Vials are usually warmed to room temperature before opening so that condensation does not form on the powder. Supplier documentation commonly specifies -20 °C for routine storage, with -80 °C used for material intended to be archived for years.

Related pages on this site

Origins and Proposed Mechanisms

Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.

Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.

Identity and Structural Background

Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.

Proposed Mechanisms and Research Endpoints

Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.

Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.

Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.

Background from the literature

=== Anti-jamming technologies === The British had been aware that the Germans would determine the purpose of the system and attempt to interfere with it, and had designed in a variety of features and methods in order to address some of these issues even as the first stations were being built. The most obvious of these was CH's ability to operate on different frequencies, which was added to allow the stations to avoid any sort of continuous-broadcast interference on their operating frequency. Additionally, the Interference Rejection Unit, or IFRU, allowed the output of the intermediate stages of the amplifiers to be clipped in an attempt to finely tune the receiver to the station's own signals and help reject broadband signals. More complex was a system built into the CH displays, implemented in order to remove spurious signals from unsynchronized jamming pulses. It consisted of two layers of phosphor in the CRT screen, a quick-reacting layer of zinc sulphide below, and a slower "afterglow" layer of zinc cadmium sulphide on top. During normal operation the bright blue signal from the zinc sulphide was visible, and its signal would activate the yellow zinc cadmium sulphide layer, causing an "averaged" signal to be displayed in yellow. To filter out jamming pulses, a yellow plastic sheet was placed in front of the display, rendering the blue display invisible and revealing the dimmer yellow averaged signal. This is the reason many radars from the War through to the 1960s have yellow displays.

Hydrogen gas production. Glycerine acetate is a potential fuel additive. Additive for starch thermoplastic. Conversion to various other chemicals: Propylene glycol Acrolein Ethanol Epichlorohydrin, a raw material for epoxy resins

CPT-symmetry puts strong constraints on the relative properties of particles and antiparticles and, therefore, is open to stringent tests. For example, the charges of a proton and antiproton must sum to exactly zero. This equality has been tested to one part in 108. The equality of their masses has also been tested to better than one part in 108. By holding antiprotons in a Penning trap, the equality of the charge-to-mass ratio of protons and antiprotons has been tested to one part in 6×109. The measured magnetic moments of protons and antiprotons have been found to be equal and opposite within 0.8 ppm.

Sources: en.wikipedia.org

Further detail

Myasthenia gravis (MG) is a long-term neuromuscular junction disease that leads to varying degrees of skeletal muscle weakness. The most commonly affected muscles are those of the eyes, face, and swallowing. It can result in double vision, drooping eyelids, and difficulties in talking and walking. Onset can be sudden. A small percentage of patients can have an enlarged thymus or rarely a thymoma. Myasthenia gravis is an autoimmune disease of the neuromuscular junction which results from antibodies that block or destroy nicotinic acetylcholine receptors (AChR) at the junction between the nerve and muscle. This prevents nerve impulses from triggering muscle contractions. Most cases are due to immunoglobulin G1 (IgG1) and IgG3 antibodies that attack AChR in the postsynaptic membrane, causing complement-mediated damage and muscle weakness. Rarely, an inherited genetic defect in the neuromuscular junction results in a similar condition known as congenital myasthenia. Babies of mothers with myasthenia may have symptoms during their first few months of life, known as neonatal myasthenia or more specifically transient neonatal myasthenia gravis. Diagnosis can be supported by blood tests for specific antibodies, the edrophonium test, electromyography (EMG), or a nerve conduction study. Mild forms of myasthenia gravis may be treated with medications known as acetylcholinesterase inhibitors, such as neostigmine and pyridostigmine. But these drugs only provide symptomatic relief.

1993/59) Friendly Societies (Qualifications of Actuaries) Regulations 1993 (S.I. 1993/60) National Rivers Authority (Levies) Regulations 1993 (S.I. 1993/61) A23 Trunk Road (Brighton Road, Croydon) (Box Junction) Order 1993 (S.I. 1993/62) Drivers' Hours (Passenger and Goods Vehicles) (Exemption) Regulations 1993 (S.I. 1993/66) Community Drivers' Hours (Passenger and Goods Vehicles) (Temporary Exception) Regulations 1993 (S.I. 1993/67) Licensed Betting Offices (Amendment) Scotland Regulations 1993 (S.I. 1993/68) Merchant Shipping (Navigational Equipment) Regulations 1993 (S.I. 1993/69) Hill Livestock (Compensatory Allowances) (Amendment) Regulations 1993 (S.I. 1993/70) Combined Probation Areas (Cornwall) Order 1993 (S.I. 1993/71) Education (Training Grants) Regulations 1993 (S.I. 1993/72) Copyright (Recording for Archives of Designated Class of Broadcasts and Cable Programmes) (Designated Bodies) Order 1993 (S.I. 1993/74) Housing Revenue Account General Fund Contribution Limits (Scotland) Order 1993 (S.I. 1993/75) A435 Trunk Road (Alcester to Gorcott Hill) De-Trunking Order 1993 (S.I. 1993/80) A435 Trunk Road (Studley Bypass and Slip Roads) Order 1993 (S.I. 1993/81) Environmentally Sensitive Areas (North Kent Marshes) Designation Order 1993 (S.I. 1993/82) Environmentally Sensitive Areas (Exmoor) Designation Order 1993 (S.I. 1993/83) Environmentally Sensitive Areas (Avon Valley) Designation Order 1993 (S.I. 1993/84) Environmentally Sensitive Areas (Lake District) Designation Order 1993 (S.I.

== Risk factors == Hospitals are primary transmission sites for CRE-based infections. Up to 75% of hospital admissions attributed to CRE were from long-term care facilities or transferred from another hospital. Suboptimal maintenance practices are the largest cause of CRE transmission. This includes the failure to adequately clean and disinfect medication cabinets, other surfaces in patient rooms, and portable medical equipment, such as X-ray and ultrasound machines that are used for both CRE and non-CRE patients. Thus far, CRE have primarily been nosocomial infectious agents. Almost all CRE infections occur in people receiving significant medical care in hospitals, long-term acute care facilities, or nursing homes. Independent risk factors for CRE infection include use of beta-lactam antibiotics and the use of mechanical ventilation. Patients with diabetes have also been shown to be at an elevated risk for acquiring CRE infections. When compared to other hospitalized patients, those admitted from long-term acute care (LTAC) facilities have significantly higher incidence of colonization and infection rates. Another 2012 multicenter study found that over 30% of patients with recent exposure to LTAC were colonized or infected with CRE. A person susceptible to CRE transmission is more likely to be female, have a greater number of parenteral nutrition-days (days when the person received nutrition via the bloodstream), and to have had a significant number of days breathing through a ventilator.

Amyloid is formed through the polymerization of hundreds to thousands of monomeric peptides or proteins into long fibers. Amyloid formation involves a lag phase (also called nucleation phase), an exponential phase (also called growth phase) and a plateau phase (also called saturation phase), as shown in the figure. When the quantity of fibrils is plotted versus time, a sigmoidal time course is observed reflecting the three distinct phases. In the simplest model of 'nucleated polymerization' (marked by red arrows in the figure below), individual unfolded or partially unfolded polypeptide chains (monomers) convert into a nucleus (monomer or oligomer) via a thermodynamically unfavourable process that occurs early in the lag phase. Fibrils grow subsequently from these nuclei through the addition of monomers in the exponential phase. A different model, called 'nucleated conformational conversion' and marked by blue arrows in the figure below, was introduced later on to fit some experimental observations: monomers have often been found to convert rapidly into misfolded and highly disorganized oligomers distinct from nuclei. Only later on, will these aggregates reorganise structurally into nuclei, on which other disorganised oligomers will add and reorganise through a templating or induced-fit mechanism (this 'nucleated conformational conversion' model), eventually forming fibrils.

Sources: en.wikipedia.org

Background from the literature

Cerebral creatine deficiencies (CCDs) are a small group of inherited disorders that result from defects in creatine biosynthesis and transport. Commonly affected tissues include the brain and muscles. There are three distinct CCDs. The most common is creatine transporter deficiency (CTD), an X-linked disorder caused by pathogenic variants in creatine transporter SLC6A8. The main symptoms of CTD are intellectual disability and developmental delay, and these are caused by a lack of creatine in the brain, due to the defective transporter. There are also two enzymatic defects of creatine biosynthesis, arginine:glycine amidinotransferase deficiency (AGAT deficiency), caused by variants in GATM gene and guanidinoacetate methyltransferase deficiency (GAMT deficiency), caused by variants in GAMT gene. The two single enzyme defects are both inherited in an autosomal recessive manner.

== Drafting == Declassification of British government archives has allowed scholars to piece together the choreography of the drafting of the declaration; in his widely cited 1961 book, Leonard Stein published four previous drafts of the declaration. The drafting began with Weizmann's guidance to the Zionist drafting team on its objectives in a letter dated 20 June 1917, one day following his meeting with Rothschild and Balfour. He proposed that the declaration from the British government should state: "its conviction, its desire or its intention to support Zionist aims for the creation of a Jewish national home in Palestine; no reference must be made I think to the question of the Suzerain Power because that would land the British into difficulties with the French; it must be a Zionist declaration." A month after the receipt of the much-reduced 12 July draft from Rothschild, Balfour proposed a number of mainly technical amendments. The two subsequent drafts included much more substantial amendments: the first in a late August draft by Lord Milner – one of the original five members of Lloyd George's War Cabinet as a minister without portfolio – which reduced the geographic scope from all of Palestine to "in Palestine", and the second from Milner and Amery in early October, which added the two "safeguard clauses".

As a mineral, native sulfur under salt domes is thought to be a fossil mineral resource, produced by the action of anaerobic bacteria on sulfate deposits. It was removed from such salt-dome mines mainly by the Frasch process. In this method, superheated water was pumped into a native sulfur deposit to melt the sulfur, and then compressed air returned the 99.5% pure melted product to the surface. Throughout the 20th century this procedure produced elemental sulfur that required no further purification. Due to a limited number of such sulfur deposits and the high cost of working them, this process for mining sulfur has not had significant use anywhere in the world since 2002.

The FBI quickly identified the hijackers, including leader Atta, when his luggage was discovered at Boston's Logan Airport. Atta had been forced to check two of his three bags due to space limitations on the 19-seat commuter flight he took to Boston. Due to a new policy instituted to prevent flight delays, the luggage failed to make it aboard American Airlines Flight 11 as planned. The luggage contained the hijackers' names, assignments, and al-Qaeda connections. "It had all these Arab-language [sic] papers that amounted to the Rosetta stone of the investigation," said one FBI agent. Within hours of the attacks, the FBI released the names and in many cases the personal details of the suspected pilots and hijackers. Abu Jandal, who served as bin Laden's chief bodyguard for years, confirmed the identity of seven hijackers as al-Qaeda members during interrogations with the FBI on September 17. He had been jailed in a Yemeni prison since 2000. On September 27, photos of all 19 hijackers were released, along with information about possible nationalities and aliases. Fifteen of the men were from Saudi Arabia, two were from the United Arab Emirates, one was from Egypt, and one was from Lebanon.

==== Clostridioides difficile diarrhea ==== The first study on dogs used for the detection of infectious diseases was conducted by Bomers et al. in 2012. The dogs were trained with food rewards to detect individuals with C. difficile diarrhea, and the results showed 100% specificity and sensitivity in the detection in stool samples. They were also capable of surveilling C. difficile in the environment with 92.3% sensitivity and 95.4% specificity for both odor detection and the ability to locate the source. Vancouver Canada hospital's canine scent recognition program also reported observing dogs' promising ability to detect C. difficile on hospital surfaces, equipment, and C. difficile reservoirs. The advantage of using trained dogs to detect C. difficile compared to the traditional culture-based diagnostic method is the fast detection speed, which only takes a few minutes. Whether sniffing dogs could be universally employed for diagnosing C. difficile is dubious as although it yields the results faster than the preexisting nucleic amplification test, its responsiveness is significantly lower.

Sources: en.wikipedia.org

Frequently asked questions

How is the peptide typically administered in studies?

Most published work uses intranasal application, either as drops or as a nasal spray. Injection routes appear in a smaller set of animal experiments. Oral use is uncommon in the literature because peptide breakdown and poor absorption limit this route.

What do the human studies show?

Reported human trials are few, brief and originate mainly from one country. They describe effects on anxiety-related measures, but sample sizes are small and reporting is limited. The results are widely regarded as preliminary rather than confirmed.

How is sample identity verified?

Reverse-phase liquid chromatography is used to assess purity and separation of related impurities. Mass spectrometry confirms that the observed molecular mass matches the expected peptide. A certificate of analysis from the supplier is the usual document of record.

How is purity determined?

Purity is usually reported as an HPLC area percentage, most often measured at 214 nm. Identity is confirmed separately by mass spectrometry. A certificate of analysis should state both the method and the observed value.

Network